- Home
- RDCM vs DSGN Comparison
RDCM vs DSGN Comparison
Compare RDCM & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- DSGN
- Stock Information
- Founded
- RDCM 1985
- DSGN 2017
- Country
- RDCM Israel
- DSGN United States
- Employees
- RDCM N/A
- DSGN N/A
- Industry
- RDCM Computer peripheral equipment
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- RDCM Technology
- DSGN Health Care
- Exchange
- RDCM Nasdaq
- DSGN Nasdaq
- Market Cap
- RDCM 203.7M
- DSGN 208.9M
- IPO Year
- RDCM 1997
- DSGN 2021
- Fundamental
- Price
- RDCM $13.82
- DSGN $5.83
- Analyst Decision
- RDCM Strong Buy
- DSGN
- Analyst Count
- RDCM 1
- DSGN 0
- Target Price
- RDCM $18.00
- DSGN N/A
- AVG Volume (30 Days)
- RDCM 52.5K
- DSGN 201.9K
- Earning Date
- RDCM 11-12-2025
- DSGN 11-06-2025
- Dividend Yield
- RDCM N/A
- DSGN N/A
- EPS Growth
- RDCM 79.61
- DSGN N/A
- EPS
- RDCM 0.56
- DSGN N/A
- Revenue
- RDCM $66,334,000.00
- DSGN N/A
- Revenue This Year
- RDCM $18.07
- DSGN N/A
- Revenue Next Year
- RDCM $11.52
- DSGN N/A
- P/E Ratio
- RDCM $23.90
- DSGN N/A
- Revenue Growth
- RDCM 18.18
- DSGN N/A
- 52 Week Low
- RDCM $9.81
- DSGN $2.60
- 52 Week High
- RDCM $15.98
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- RDCM 47.65
- DSGN 44.21
- Support Level
- RDCM $13.05
- DSGN $5.67
- Resistance Level
- RDCM $14.16
- DSGN $7.21
- Average True Range (ATR)
- RDCM 0.55
- DSGN 0.57
- MACD
- RDCM -0.09
- DSGN -0.14
- Stochastic Oscillator
- RDCM 37.16
- DSGN 7.14
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.